ACADIA Pharmaceuticals Inc (ACAD)vsAlnylam Pharmaceuticals Inc (ALNY)
ACAD
ACADIA Pharmaceuticals Inc
$22.01
+5.01%
HEALTHCARE · Cap: $3.57B
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 247% more annual revenue ($3.71B vs $1.07B). ACAD leads profitability with a 36.5% profit margin vs 8.5%. ACAD trades at a lower P/E of 9.1x. ACAD earns a higher WallStSmart Score of 66/100 (B-).
ACAD
Strong Buy66
out of 100
Grade: B-
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+79.1%
Fair Value
$107.64
Current Price
$22.01
$85.63 discount
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 40 in profit
Keeps 37 of every $100 in revenue as profit
Earnings expanding 86.2% YoY
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Negative free cash flow — burning cash
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACAD
The strongest argument for ACAD centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 36.5% and operating margin at 6.1%.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : ACAD
The primary concerns for ACAD are Piotroski F-Score, PEG Ratio, Free Cash Flow.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Key Dynamics to Monitor
ACAD profiles as a mature stock while ALNY is a hypergrowth play — different risk/reward profiles.
ACAD carries more volatility with a beta of 0.81 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ACAD scores higher overall (66/100 vs 49/100), backed by strong 36.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ACADIA Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?